AUTHORS
David Aaron Russler-Germain, MD, PhD, Fei Wan, PhD2, Beth Reagan3, Isabela Granjeno4, Michelle Becker-Hapak5, Joseph Rueve6, Sushanth Pureti7, Hunter Cassidy Cochran, MD8, Dilan Anil Patel, MD9, Brad S. Kahl, MD10, Neha Mehta-Shah, MD, MSCI11, Todd Fehniger, MD, PhD12, Nancy L. Bartlett, MD13
AFFILIATIONS
1 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 Washington University School of Medicine, St. Louis, Missouri, United States
8 Washington University School of Medicine, St. Louis, Missouri, United States
9 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
10 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
11 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
12 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
13 Siteman Cancer Center, St. Louis, Missouri, United States, Washington University School of Medicine, St. Louis, Missouri, United States
ABSTRACT
Background: Mosunetuzumab (Mosun) is an anti-CD3xCD20 bispecific antibody approved as intravenous (IV) or subcutaneous (SC) treatment for patients (pts) with relapsed/refractory (r/r) follicular lymphoma (FL) after 2+ lines of therapy. Polatuzumab vedotin (Pola) is an anti-CD79b antibody-drug conjugate approved as IV treatment combined with rituximab (R) and chemotherapy in frontline and r/r diffuse large B cell lymphoma (DLBCL). A recent randomized phase 3 study of Mosun + Pola in transplant-ineligible pts with r/r DLBCL showed superiority over R + gemcitabine/oxaliplatin (Budde JCO 2025). Given non-overlapping toxicities and motivation to spare pts with FL from traditional chemotherapy, we designed a phase 2 study of Mosun + Pola as frontline systemic therapy for pts with high tumor burden (HTB) FL. Here we report 2-year follow-up with full accrual (preliminary results were presented at ASH 2024).
Methods: For this single center, investigator-initiated phase 2 trial (NCT05410418), key inclusion criteria were diagnosis of FL gr1–3A, no prior systemic therapy, HTB by GELF criteria, and stage II–IV disease. Mosun was administered by SC injection on 21-day cycles (C). In C1, Mosun was given Day (D) 1 (5mg), D8 (45mg) and D15 (45mg). In C2+, Mosun was given D1 only (45mg). Pola was administered by IV infusion C1–C6 on D1 at 1.8mg/kg. Premedications were acetaminophen/diphenhydramine on all treatment days, with palonosetron added before Pola doses. Dexamethasone 20mg was given before all C1 Mosun doses (optional thereafter). All pts received concurrent Mosun + Pola, with interim assessment by FDG PET-CT post-C2 (PET2). Pts with progression or inadequate response by PET2 discontinued therapy; all others completed Mosun through C8 and Pola through C6 before another FDG PET-CT (PET8). Pts achieving complete response (CR) by PET8 stop treatment; pts with partial response (PR) or stable disease by PET8 could continue Mosun through C17 at physician discretion. The primary endpoint was CR rate by Lugano 2014 criteria.
Results: From 10/2022–4/2025, 34 pts enrolled (age >60: 71%; stage IV: 68%; bulky >7 cm: 35%; B symptoms: 21%; FLIPI 0–1: 9%; FLIPI 2: 41%; FLIPI 3–5: 50%). At data cutoff (7/2026), median follow-up was 25.4 months (range: 1.6–41.9). All pts had at least one post-baseline tumor assessment. All treatment was administered outpatient. No pt remains on study therapy.
Overall response rate was 94.1% (32/34; 95% CI: 80.3–99.2%) and complete response rate was 88.2% (30/34; 95% CI: 72.6–96.7%). Twenty (58.8%) pts achieved CR by PET2, while 90.9% (10/11) of pts in PR at PET2 converted to CR at PET8. All patients (including 2 PRs) stopped treatment post-C8. Median DOR and PFS have not been reached. Estimated 24-month DOR is 89.7% (95%CI 79.2–100%) and 24-month PFS is 87.2% (95%CI 76.2–99.8%). Both non-responders achieved CR to second-line anti-CD20 mAb + chemotherapy.
Common adverse events (AEs), irrespective of attribution, included injection site reaction (71%; gr1: 62%, gr2: 9%; no gr3+), cytokine release syndrome (CRS; 59%; gr1: 56%; gr2: 3%; no gr3+), nausea (50%; gr1: 47%; gr2: 3%; no gr3+), diarrhea (50%; gr1: 35%; gr2: 6%; gr3+: 9%), upper respiratory infection (URI; 32%; gr1: 6%; gr2: 24%; gr3+: 3%), and peripheral neuropathy (38%; gr1: 32%; gr2: 6%; no gr3+). Gr3+ neutropenia occurred in 24% of pts. Serious AEs were gr4 neutropenia (n=1), gr3 diarrhea (n=1), gr3 abdominal pain (n=1), gr3 febrile neutropenia (n=1), gr2–3 URI (n=2), gr2 extravasation (n=1), gr2 pneumonitis (n=1), gr1–2 CRS (n=4), pregnancy loss (n=1; >1 year post-EOT), and myelodysplastic syndrome (n=1; analysis of PBMCs from pre-C1D1 showed pathogenic variants in DNMT3A, JAK2, TET2, NF1, ZRSR2).
Mosun AEs of special interest (SI) included gr3 bilirubin elevation (n=2), gr3 vasovagal event (n=1), gr3 febrile neutropenia (n=1), gr2 ALT increase (n=2), gr2 headache (n=1), gr2 CRS (n=1), gr2 pneumonitis (n=1), and gr1 pneumonitis (n=1). Pola AEs of SI were gr2 peripheral neuropathy (n=2). Three pts discontinued treatment due to AEs (gr3 URI, n=1; gr2 pneumonitis, n=1; gr2 chills/rigors, n=1). No pt experienced AEs consistent with ICANS. All patients remain alive.
Conclusions: This 2-year analysis of Mosun + Pola for frontline treatment in HTB FL demonstrated a high CR rate (88%), durable remissions (90% 2-year DOR), and toxicity aligning with prior reports. This study met its primary endpoint, and this antibody-based regimen is encouraging for further study.
DISCLOSURES
David Aaron Russler-Germain, MD, PhD: Abbvie - Consultancy (Includes expert testimony); Tempus - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Natera - Consultancy (Includes expert testimony)